Anthranylalkyl and cycloalkyl amides and use thereof as VEGF receptor inhibitors

US6818661B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Dieter Seidelmann · Berlin, DE
• Martin Kruger · Berlin, DE
• Eckhard Ottow · Berlin, DE
• Andreas Huth · Berlin, DE
• Karl-Heinz Thierauch · Berlin, DE
• Andreas Menrad · Berlin, DE
• Martin Haberey · Berlin, DE

Key dates

• Filing date: May 9, 2003
• Grant date: Nov 16, 2004
• Expiry date: May 9, 2023

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P9/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention relates to substituted anthranylalkyl and cycloalkyl amides of general formula (I) and to their use as medicaments for treating diseases caused by persistent angiogenesis.